This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 3 of 148

After Exubera, Uncertainty Reigns

By Robert Steyer

Pfizer's decision to drop inhaled insulin could dim the prospects for competing products.

04:01PM 10/22/07

Hot Art From the Arctic

By Robert Steyer

Inuit prints from northern Canada offer a beautiful -- and affordable -- investment.

09:47AM 10/19/07

Can Good Health Last for Medical IPOs?

By Robert Steyer

The first part of the year was solid for new biotechs and health stocks.

02:20PM 09/11/07

Challenges Persist for Glaxo

By Robert Steyer

Fans say the company is too big to fail, but it's also too big to grow much without developing more hits.

04:43PM 08/22/07

J&J's Risperdal Gets New Uses

By Robert Steyer

The drug is approved by the FDA for younger patients.

04:35PM 08/22/07

Pfizer Finds New CFO

By Robert Steyer

Frank D'Amelio will join the company from Alcatel-Lucent.

11:18AM 08/22/07

FDA Approves Novartis Osteoporosis Drug

By Robert Steyer

Reclast is a once-a-year treatment.

05:19PM 08/20/07

Glaxo Drug Gets Black Box

By Robert Steyer

Avandia will carry a new warning.

05:38PM 08/14/07

Wyeth Whacked on Drug Setbacks

By Robert Steyer

It gets bad news from the FDA and pulls a hepatitis C drug candidate.

01:49PM 08/10/07

One Giant Leap for MannKind

By Robert Steyer

The company will sell $350 million in debt, warrants and stock.

05:48PM 08/09/07

Page 3 of 148

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs